Mason Lankes

Mason Lankes
Celcuity Makes Monumental Progress in Advancing Clinical Development of Gedatolisib for HR-Positive, HER2-Negative Advanced Breast Cancer

CELC

Celcuity Makes Monumental Progress in Advancing Clinical Development of Gedatolisib for HR-Positive, HER2-Negative Advanced Breast Cancer

Celcuity continues to make significant strides in advancing clinical development of its flagship therapy, gedatolisib, for patients with HR-positive, HER2-negative advanced breast cancer. The company's latest quarterly update highlights a series of impressive milestones achieved in the second quarter of 2026. According to Brian Sullivan, CEO of Celcuity,

By Mason Lankes
Eton Pharmaceuticals Achieves Record-Breaking Second Quarter with 99% Revenue Growth and Significant Margin Expansion

ETON

Eton Pharmaceuticals Achieves Record-Breaking Second Quarter with 99% Revenue Growth and Significant Margin Expansion

On August 13, 2026, Eton Pharmaceuticals announced its exceptional second quarter financial results, showcasing record revenue growth, significant margin expansion, and notable progress across both its commercial portfolio and pipeline. The company's Chief Executive Officer, Sean Brynjelsen, highlighted several key accomplishments during the conference call. The company achieved

By Mason Lankes